A recent article in Nature Biotechnology (by Nahmad AD1, Reuveni et al., “Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage”, June 30, 2022) reports on the risks and benefits of the therapeutic use of CRISPR-Cas9 “gene scissors” technology.
A comment on the Nature article published in the Jerusalem Post explains: “CRISPR – an acronym for ‘clustered regularly interspaced short palindromic repeats’ – allows genetic material to be added, removed or altered…
